The FITCH trial investigated the efficacy of bezafibrate, a broad peroxisome proliferator-activated receptor (PPAR) agonist, in alleviating moderate to severe pruritus in patients with fibrosing cholangiopathies, including primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), and secondary sclerosing cholangitis (SSC). Conducted between 2016 and 2019 as a multicenter, double-blind, randomized, placebo-controlled trial, it enrolled 74 adults with pruritus ≥5/10 on a visual analog scale (VAS).
The FITCH trial investigated the efficacy of bezafibrate, a broad peroxisome proliferator-activated receptor (PPAR) agonist, in alleviating moderate to severe pruritus in patients with fibrosing cholangiopathies, including primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), and secondary sclerosing cholangitis (SSC). Conducted between 2016 and 2019 as a multicenter, double-blind, randomized, placebo-controlled trial, it enrolled 74 adults with pruritus ≥5/10 on a visual analog scale (VAS). Patients received either bezafibrate 400 mg daily or placebo for 21 days.
The primary endpoint, a ≥50% reduction in itch intensity, was achieved by 45% of bezafibrate-treated patients compared to 11% in the placebo group (P=0.003). Secondary measures, including daily VAS scores and pruritus questionnaires (5D-Itch, Liver Disease Symptom Index 2.0), confirmed significant improvements in itch severity, sleep quality, and daily functioning. Bezafibrate also reduced serum alkaline phosphatase (ALP) by 35% versus a 6% increase in the placebo group (P=0.03), correlating strongly with pruritus relief. Gamma-glutamyl transferase (GGT) and ALT levels improved, while bile acids and autotaxin levels remained unchanged, suggesting the antipruritic effect was independent of these pathways.
Bezafibrate was effective across PSC, PBC, and varying pruritus severities, with comparable benefits in cirrhotic and non-cirrhotic patients. It was well-tolerated, with mild side effects such as transient mouth pain and back pain. The study concluded that bezafibrate offers a promising short-term treatment for cholestatic pruritus, with its antipruritic and anticholestatic effects likely mediated through PPAR activation. Long-term studies are needed to confirm its sustained efficacy and safety.
Introduction: Acute kidney injury (AKI) is a frequent and life-threatening complication of cirrhosis, with management often complicated by inaccurate assessment of intravascular volume and the presence of cirrhotic cardiomyopathy (CCM). This prospective study evaluated whether...
Introduction: Acute-on-chronic liver failure (ACLF) is characterized by overwhelming systemic inflammation and immune dysregulation, leading to high short-term mortality. This study used advanced single-cell and spatial transcriptomic technologies to define the immune landscape of ACLF...
Introduction: Adults with Fontan-type circulation are increasingly recognized to develop Fontan-associated liver disease and portal hypertension. This prospective study explored the prevalence, anatomical distribution, and hemodynamic characteristics of esophageal varices (EV), with particular emphasis on...
Introduction: Acute-on-chronic liver failure (ACLF) is characterized by overwhelming systemic inflammation and immune dysregulation, leading to high short-term mortality. This study used advanced single-cell and spatial transcriptomic technologies to define the immune landscape of ACLF...
Introduction: Despite advances in the management of portal hypertension, mortality after variceal bleeding remains high in patients with cirrhosis. Experimental and clinical studies suggest that statins may improve portal hypertension and hepatic vascular function. This...
Introduction: Acute liver failure (ALF) complicated by cerebral oedema carries a high risk of early mortality, primarily due to hyperammonemia and intracranial hypertension. The optimal timing of continuous renal replacement therapy (CRRT) in these critically...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.